Rapamycin News and Research

RSS
Rapamycin is a drug used to prevent the rejection of organ and bone marrow transplants by the body. Rapamycin is an antibiotic that blocks a protein involved in cell division and inhibits the growth and function of certain T cells of the immune system involved in the body's rejection of foreign tissues and organs. It is a type of immunosuppressant and a type of serine/threonine kinase inhibitor. Rapamycin is now called sirolimus.
HKUST scientists find way to stimulate growth of corticospinal tract axons

HKUST scientists find way to stimulate growth of corticospinal tract axons

Researchers discover mechanism that regulates metabolism

Researchers discover mechanism that regulates metabolism

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

Rapamycin drug reduces obesity, preserves lean body mass in older rats

Rapamycin drug reduces obesity, preserves lean body mass in older rats

TSRI scientists awarded $2.1 million grant to study protein closely linked to Parkinson's disease

TSRI scientists awarded $2.1 million grant to study protein closely linked to Parkinson's disease

UAB study finds how genetic variation in IIS/TOR molecular network may regulate variation in metabolism

UAB study finds how genetic variation in IIS/TOR molecular network may regulate variation in metabolism

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Scientists reveal why lone kidney gets bigger when the other one is lost

Scientists reveal why lone kidney gets bigger when the other one is lost

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

IMDC prognostic model valid in second-line RCC therapy

IMDC prognostic model valid in second-line RCC therapy

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

Research opens door to development of new therapies to block HIV-associated neurocognitive disorders

Research opens door to development of new therapies to block HIV-associated neurocognitive disorders

Researchers identify molecular pathways that could lead to new therapeutic targets for cerebral malaria

Researchers identify molecular pathways that could lead to new therapeutic targets for cerebral malaria

New nationwide effort seeks to find novel approaches to treat ASD, intellectual disability

New nationwide effort seeks to find novel approaches to treat ASD, intellectual disability

Metastatic RCC patients may benefit from sequential TKI strategy

Metastatic RCC patients may benefit from sequential TKI strategy

Joslin study could lead to improved anti-aging drugs

Joslin study could lead to improved anti-aging drugs

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.